Some of the names on the move ahead of the open.» Read More
The Fast Money traders told you the bottom won’t be in, until there’s panic like never before. Wait...
Talk about timely direct-to-consumer advertising. Last week ,I blogged about AstraZeneca's new ad campaign for FluMist and its tie-in with the back-to-school shopping season. Well, now the drugmaker is getting political.
Ads for flu vaccines have traditionally been confined to PSAs, health and media alerts. So that's why I was surprised to see this colorful full-page ad in The New York Times this weekend for FluMist from AstraZeneca/MedImmune. Why..?
The market cap of Dow component Johnson & Johnson is a whopping $200 billion. Abbott Labs is valued at less than half that. But think of ABT as kind of a mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products.
Although a longshot in winning the gold in our World Markets Challenge, the UK's FTSE 100 is now less than 1% behind the S&P 500 on the leaderboard. Here are some key stats on Britain's economy and markets.
Drugmaker AstraZeneca, enjoying a favorable tailwind from currencies, lifted its full-year earnings forecast on Thursday as second-quarter results came in ahead of expectations.
Roche Holdings' $43.7 billion bid to buy the rest of Genentech highlights drugmakers' growing reliance on biotech products.
Swiss drugmaker Roche Holding offered to acquire all outstanding shares in its U.S. partner Genentech for $43.7 billion in cash to reinforce its position in cancer medicines.
The S&P closed 20% below its all-time high set in October, making it the last of the three major U.S. stock indexes to fall into a bear market. What's the "Word on the Street?"
Following are the day’s biggest winners and losers. Find out why shares of Chesapeake Energy and AstraZeneca popped while Circuit City and Western Union dropped.
Stocks limped to the finish of an ugly week on Wall Street, with the Dow touching bear territory and the broader market continuing to be battered by a double dose of surging oil and a fresh round of banking troubles.
I'm thinkin' those two drug giants are champin' at the bit for the docs to get McCain off generic Zocor and onto Lipitor or Crestor. On recent conference calls, some PFE officials have said they think a lot of patients who've had a similar experience to McCain's will eventually come back around to Lipitor.
If sales of Amgen's anemia drugs hadn't fallen so much last year, the American biotechnology industry probably would have turned its first profit in history. That's one of the main conclusions of Ernst & Young's comprehensive annual report on the sector that came out today.
Following are the day’s biggest winners and losers. Find out why shares of Nike and BHP Billiton popped while Whole Foods and American Apparel dropped.
As the market gets a jolt of confidence on Mars’ plans to buy Wrigley, CNBC asked the experts how to make the most of the momentum.
For investors right now, the best offense is a good defense. That's how John Dorfman of the Dorfman Value Fund and Thunderstorm Capital sees it.
AstraZeneca nudged up its forecast for 2008 earnings on Thursday, but sales of key products in the first quarter were weaker than hoped for, knocking its shares.
This halftime report is not brought to you by (pick your prescription drug). So, we're pretty much at the midway point of big pharma's earnings season and Goldman Sachs analyst James Kelly is sizing things up so far...
Stocks close mixed as quarterly results from Bank of America and National City fueled worries about bank earnings, while energy and tech gained.
Stocks started the week lower, hurt by more uncertainty in the banking industry and earnings report that left investors wary after coming off a strong rally last week.